The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly
ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/
small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL),
mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenstrm's macroglobulinemia
This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort
Expansion (Part 2). Following determination of a recommended phase 2 dose (RP2D) in Part 1,
the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.